A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity

Gynecologic Oncology

Volumn 91, Issue 2, 2003, Pages 435-437

  McElroy, Tara M ^a   Von Gruenigen, Vivian E ^a   Waggoner, Steven E ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Carboplatin; Hypersensitivity reaction; Ovarian cancer

Indexed keywords

ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; ONDANSETRON; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; COUGHING; DESENSITIZATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; HOT FLUSH; HUMAN; HUMAN TISSUE; LABORATORY TEST; LAPAROTOMY; OVARIECTOMY; PERITONEUM CANCER; PLEURA EFFUSION; PREMEDICATION; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TUMOR BIOPSY; WHEEZING;

EID: 0242321025     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00541-9     Document Type: Article

References (10)

1. Rose P., Fusco N., Fluellen Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 16:(4):1998;1494-1497.
2. Zanotti K., Markman M. Prevention and management of antineoplastic- induced hypersensitivity reactions. Drug Saf. 24:(10):2001;767-779.
3. Markman M., Kennedy A., Webster K., Elson P., Peterson G., Kulp B., et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 17:1999;1141-1145.
4. Weidmann B., Muellenstein N., Bojko P., Niederle N. Hypersensitivity reactions to carboplatin. Cancer. 73:(8):1994;2218-2222.
5. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol. 65:1997;434-436.
6. Goldberg A., Confino-Cohen R., Fishman A., Beyth Y., Altaras M. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol. 96:(4):1996;841-843.
7. Robinson J., Singh D., Bodurka-Beevers D., Wharton T., Gershenson D., Wolf J. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol. 82:(3):2001;550-558.
8. Rose P., Fusco N., Fluellen L., Rodriguez M. Carboplatin hypersensitivity reaction in patients with ovarian and peritoneal carcinoma. Int Gynecol Cancer. 8:1998;365-368.
9. Markman M. Letter to the editor. Gynecol Oncol. 84:(2):2002;353.
10. ICON2: randomized trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm study. Lancet 1998;352(9140): 1571-6.